Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

2-1-2020

G protein-coupled kisspeptin receptor induces metabolic
reprograming and tumorigenesis in estrogen receptor-negative
breast cancer
Magdalena Dragan
Rutgers Robert Wood Johnson Medical School at New Brunswick

Mai Uyen Nguyen
Rutgers Robert Wood Johnson Medical School at New Brunswick

Stephania Guzman
Rutgers Robert Wood Johnson Medical School at New Brunswick

Cameron Goertzen
University of Toronto

Muriel Brackstone
London Health Sciences Centre

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Dragan, Magdalena; Nguyen, Mai Uyen; Guzman, Stephania; Goertzen, Cameron; Brackstone, Muriel;
Dhillo, Waljit S.; Bech, Paul R.; and Clarke, Sophie, "G protein-coupled kisspeptin receptor induces
metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer" (2020).
Paediatrics Publications. 1955.
https://ir.lib.uwo.ca/paedpub/1955

Authors
Magdalena Dragan, Mai Uyen Nguyen, Stephania Guzman, Cameron Goertzen, Muriel Brackstone, Waljit S.
Dhillo, Paul R. Bech, and Sophie Clarke

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/1955

Dragan et al. Cell Death and Disease (2020)11:106
https://doi.org/10.1038/s41419-020-2305-7

ARTICLE

Cell Death & Disease

Open Access

G protein-coupled kisspeptin receptor induces
metabolic reprograming and tumorigenesis
in estrogen receptor-negative breast cancer

1234567890():,;
1234567890():,;

1234567890():,;
1234567890():,;

Magdalena Dragan1, Mai-Uyen Nguyen 1, Stephania Guzman1, Cameron Goertzen2, Muriel Brackstone3,
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Wei-Xing Zong7,8, Frederic E. Wondisford1,7,9, Xiaoyang Su1,7, Andy V. Babwah9,10 and Moshmi Bhattacharya1,7,9

Abstract
Triple-negative breast cancer (TNBC) is a highly metastatic and deadly disease. TNBC tumors lack estrogen receptor
(ERα), progesterone receptor (PR), and HER2 (ErbB2) and exhibit increased glutamine metabolism, a requirement for
tumor growth. The G protein-coupled kisspeptin receptor (KISS1R) is highly expressed in patient TNBC tumors and
promotes malignant transformation of breast epithelial cells. This study found that TNBC patients displayed elevated
plasma kisspeptin levels compared with healthy subjects. It also provides the ﬁrst evidence that in addition to
promoting tumor growth and metastasis in vivo, KISS1R-induced glutamine dependence of tumors. In addition, tracerbased metabolomics analyses revealed that KISS1R promoted glutaminolysis and nucleotide biosynthesis by
increasing c-Myc and glutaminase levels, key regulators of glutamine metabolism. Overall, this study establishes KISS1R
as a novel regulator of TNBC metabolism and metastasis, suggesting that targeting KISS1R could have therapeutic
potential in the treatment of TNBC.

Introduction
Triple-negative breast cancer (TNBC) is a particularly
deadly subtype of breast cancer. TNBC patient survival is
limited by extensive metastasis and the frequent development of tumor resistance to available chemotherapy1.
These patients fail to respond to endocrine or anti-HER2
therapy and lack targeted therapies1. Clearly, in order to
identify clinically relevant biomarkers and develop targeted therapies, there is a vital need to better understand
molecular pathways that are distinctly activated in TNBC.
Metabolic reprogramming is a hallmark of cellular
transformation; this enables cancer cells to maintain high
proliferation rates despite ﬂuctuations in nutrient
Correspondence: Moshmi Bhattacharya (mb1722@rutgers.edu)
1
Department of Medicine, Robert Wood Johnson Medical School, Rutgers
University, New Brunswick, NJ, USA
2
Cancer Invasion and Metastasis Laboratory, Faculty of Dentistry, University of
Toronto, Toronto, ON, Canada
Full list of author information is available at the end of the article.
Edited by M. Herold

availability2. In highly proliferative cells, glutamine can
provide energy via the tricarboxylic acid (TCA) cycle, as
well as nitrogen for nucleotide biosynthesis. Glutamine is
converted to glutamate by glutaminase, the rate-limiting
enzyme in glutaminolysis3. Aggressive basal-like tumors
such as TNBC are dependent on exogenous glutamine for
survival and growth4 and high glutamate levels have been
found in human TNBC tumors5–7.
G protein-coupled receptors (GPCRs), targets for over a
third of all marketed pharmaceuticals, regulate tumorigenesis8, but little is known about their roles in regulating
tumor metabolism. The GPCR, kisspeptin 1 receptor
(KISS1R previously known as GPR54) binds kisspeptins
(KPs), a family of secreted, biologically active peptides
found in the blood9,10. KPs (10, 13, 14, or 54 amino acids)
are derived from a 145 amino acid peptide, KISS1
(encoded by the KISS1 gene) that is cleaved rapidly in the
serum by matrix metalloproteinases (MMPs) MT1-MMP,
MMP-9, and furin11,12. All KPs have similar afﬁnity for
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KISS1R; however, KP-10 is the agonist of choice for most
studies13–15. KISS1 is commonly classiﬁed as a metastasis
suppressor gene and exerts antitumorigenic roles in many
cancers10,16,17. However, when breast cells lose ERα,
KISS1R signaling promotes epithelial-to-mesenchymaltransition (EMT) and stimulates tumor invasion by
inducing invadopodia formation via MT1-MMP and the
mitogen-activated protein kinase (MAPK) pathway18,19.
KISS1R activation also induces TNBC invasion by activating the epidermal growth factor receptor, via MMP-9,
but fails to activate HER216–20.
Mechanistically, we and others have shown that ERα
negatively regulates KISS121 and KISS1R levels, as well as
KISS1R-induced invasion17–20. Therefore, in ERα-negative cancers such as TNBC, this may partly account for
the switching of KISS1R from metastasis suppressor to
promoter. This dualistic nature of signaling molecules
where they exhibit pro- and antitumor roles is not unique
to KISS1/KISS1R. For example, c-Myc22, AMP-activated
protein kinase23, and transforming growth factor β24 are
among the many reported to play dual roles, highlighting
the importance of studying cancer in context.
Recently, we reported that KISS1/KISS1R expression
are upregulated in TNBC patient tumor biopsies compared with healthy breast tissue and that KISS1R signaling
induces a drug-resistant phenotype in TNBC25. Human
TNBC cells express high levels of both KISS1 and KISS1R
compared with normal mammary epithelial cells and
secrete KP-1020,25. However, it is not known whether
plasma levels of KPs change in TNBC and whether
KISS1R regulates metastasis or tumor metabolism.
This study reveals that KISS1R signaling plays a central
and multifunctional role in ERα-negative breast cancer, by
supporting tumor growth and metastasis. It also uncovers
that KISS1R signaling metabolically reprograms cancer
cells to depend on glutamine for tumorigenesis. Speciﬁcally, KISS1R regulates the expression of the transcription
factor c-Myc and glutaminase that are necessary for glutamine catabolism and therefore drives processes such as
nucleotide synthesis required for tumor growth.
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Table 1 Clinical proﬁle of study participants (females:
healthy subjects and TNBC patients) from London Health
Science Center, London, Ontario, Canada.
Characteristics

Number (range)

KP (pmol/L) (mean ± SEM)

Normal subjects age (years) (n = 26)

Mean 34 (20–52)

39.1 ± 2.3

Early disease (nonmetastatic) TNBC age
(years) (n = 25)

Mean 54.8 (27–79)

78 ± 6.9

Tumor size (mm)

Mean 25.3 (4–55)

Blood collection
Before any treatment

18

77.83 ± 5.5

Before any surgery

21

82.55 ± 6.1

During/after chemotherapy

3

96.6 ± 7.1

After tumor removing surgery

4

68.3 ± 6.7

After radiation therapy

0

Tumor size
T1

13

T2

7

T3

1

T4

4

Node status
N0

16

N1

5

N2

2

N3

1

Nx

1

Metastatic disease TNBC age (years) (n = 27)

Mean 62.1 (40–85)

64.9 ± 6.8

No surgery (primary tumor present)

8

66.0 ± 5.5

Surgery (tumor removed)

19

64.4 ± 6.1

No chemotherapy

12

77.8 ± 5.4

Chemotherapy

13

62.1 ± 7.1

Radiation therapy

12

73.9 ± 6.6

Site of metastasis
Brain

5

Lung/pleura

12

Bone

7

Lymph nodes/lymphatics

10

frozen immediately in liquid nitrogen. Samples were
stored at −80 °C and subsequently thawed to quantify
plasma KP using a sensitive in-house radioimmunoassay,
in the Dhillo laboratory as described26. Statistical analysis
of clinical samples was conducted by a biostatistician
(Statistical Services, Western University) using a nonparametric Kruskal–Wallis test.

Methods
Blood collection and plasma kisspeptin measurements

Immunohistochemistry

The study was approved by the Ofﬁce of Human
Research Ethics, Western University and all female participants provided informed consent. Blood (5 mL) was
collected in BD Vacutainer K2 EDTA tubes (VWR
International) from the following groups: healthy subjects
(n = 26), nonmetastatic “early” TNBC patients (n = 26),
metastatic TNBC patients (n = 27) presenting to Dr. M
Brackstone’s Breast Care Clinic at St. Joseph’s Health Care
London or at the London Regional Cancer Program (see
Table 1 for patient demographics). Blood was centrifuged
at 3000 rpm for 10 min and the plasma was collected and

Parafﬁn-embedded mammary tissue from nondiseased
and breast cancer patients (TNBC) were obtained from
London Health Science Center University Hospital, London, Ontario, Canada following approval by the University of Western Ontario Research Ethics Board.
Immunohistochemical analysis of human breast tissue
was done as previously described27. In short, following
deparafﬁnization and heat induced antigen retrieval, slides
were incubated with the following antibodies: rabbit
monoclonal antikeratin 5 CST 71536 (1:1000) and mouse
monoclonal antikeratin 8/18 CST 4546 (1:100) from Cell
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Signaling Technology; rabbit monoclonal anti-c-Myc
(1:500) ab32072 and rabbit monoclonal anti-glutaminase
ab156876 (1:100) from Abcam.
Cell culture

Human cell lines were purchased from ATCC and
maintained at 37 °C with 5% CO2. ERα-negative human
breast cancer SKBR3 cells and TNBC MDA-MB-231 were
cultured in RPMI 1640 supplemented with 10% (v/v) fetal
bovine serum (FBS). Stable knockdown of KISS1R in
MDA-MB-231 cells has been previously described19.
Expression of shRNA did not affect cell viability19. SKBR3
cell lines stably expressing KISS1R (SKBR3FLAG-KISS1R)
and pFLAG vector controls were generated, as described18 and were grown in media containing G418
(1 μg/mL). KISS1R expression was veriﬁed weekly by
western blot. All stable cells lines represent polyclonal
(mixed) cell populations.
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rabbit anti-Erk (1:1000), and manti-Phospho-Erk (1:2000)
from New England Biolabs. Mouse anti-GAPDH (1:4000,
GeneTex GTX627408), anti-β actin (1:5000, Thermo
Fisher Scientiﬁc APPA6889) or anti-vinculin (1:1000, BioRad MCA465GA) were used for loading control. Protein
was then incubated for 1 h in horseradish peroxidase
(HRP)-conjugated rabbit (1:2500, Cell Signaling Technology, CST7074S) or mouse (1:2500, GE Healthcare,
NA931) secondary antibody. For ERK activation assays,
cells were serum starved for 3 h prior to 24 h treatment
with 10 μM of U0126 (active MEK1 and MEK2 inhibitor)
or U0124 (inactive U0126 analog serving as negative
control). Expression levels were imaged by chemiluminescence with SuperSignal West Dura Extended Duration
Substrate (Thermo Scientiﬁc) and ChemiDoc Touch
imaging system (Bio-Rad) and subsequently quantiﬁed
using Image Lab Software (Bio-Rad).
Xenograft assays

c-MYC depletion by siRNA

Cells were transfected with siMYC or control siRNA
(Silencer™ Select Pre-Designed siRNA, Thermo) according to manufacturer instructions. c-Myc expression was
determined by RT-qPCR and western blot analysis 48 h
and 72 h post transfection.
Immunoblot assays

Immunoblot assays were conducted as previously
described18,20. For human breast tissue and patient TNBC
tumor protein analysis, immunoblots were conducted
using TNBC biopsies obtained from Dr. Brackstone’s
London Tumor Biobank, in accordance with the Health
Sciences Research Ethics Board at the University of
Western Ontario, London, Ontario, Canada. Core tumor
tissues (10 mm × 1 mm) were collected by guided needle
biopsy and immediately frozen in liquid nitrogen and the
diagnosis was conﬁrmed by the pathologist. Normal
breast tissue (noncancerous) was also obtained from the
London Tumor Biobank. The cores were homogenized in
RIPA lysis buffer containing proteases inhibitors and
centrifuged at 4 °C and protein expression in 100 μg
lysates was analyzed by western blot analysis. The relative
expression of each protein to GADPH was also normalized to their expression in MDA-MB-231 cell lysates
(20 μg) that served as an internal control in all studies.
For cultured cells, cell lysates were prepared following
incubation in RIPA buffer for 20 min at 4 °C. Protein
(50 μg) was separated using SDS-PAGE and probed using
the following antibodies: Abcam (rabbit anti-KISS1R
(ab137483), rabbit anti-NAGS (ab65536), both 1:1000),
Cell Signaling Technology (rabbit anti-c-Myc (CST
#13987), mouse antikeratin 8/18 CST 4546, all 1:1000),
rabbit anti-glutaminase (1:500, Invitrogen 710997), rabbit
anti-glutamine synthetase (1:5000, Sigma-Aldrich G2781),
Ofﬁcial journal of the Cell Death Differentiation Association

Animal studies were performed in accordance with the
Institutional Animal Care and Use Committee (IACUC)
guidelines of Rutgers University and under a protocol
approved by the Western University Animal Care Committee with the recommendations of the Canadian
Council on Animal Care. Six-week-old female NOD/
SCIDIL2Rγ null (immunocompromised) mice were utilized for all assays and experiments were conducted as
previously described27. Sample size for xenografts was
estimated based on law of diminishing return by statistician. Mice were randomly assigned to control or experimental group, for each xenograft study (spontaneous
metastasis assay or experimental metastasis assay) and the
investigator was blinded to group allocation or when
experimental outcome was assessed. For spontaneous
metastasis assay, human metastatic TNBC MDA-MB-231
cells stably expressing scrambled control or two individual KISS1R-speciﬁc shRNA19 were resuspended in
growth factor-reduced Matrigel (1:1) (1 × 106 cells/
mouse) and injected into the right mammary fat pad of
mice. Subsequent tumor growth was measured by caliper
biweekly. At 5 weeks post injection, mice were sacriﬁced,
and primary tumor and lung tissues were harvested, ﬁxed
in 4% paraformaldehyde and embedded in parafﬁn. For
orthotopic and experimental metastasis assays, we used a
gain-of-function model using ERα-negative human SKBR3
breast cancer cells stably expressing FLAG-KISS1R or
pFLAG control cell lines generated as described18. Cells
were injected into the tail vein or mammary fat pads of 6week-old immunocompromised mice for experimental
metastasis or orthotopic xenograft models, respectively.
Mice were sacriﬁced at 3 weeks for lung colonization and
6–8 weeks to assess primary tumor growth. Lungs and
primary tumors were harvested, ﬁxed in 4% paraformaldehyde, and processed for histology as described
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previously27. Sections were stained as previously described27 using antihuman Ki67 (1:100 dilution, Thermo
Fisher Scientiﬁc), antihuman cytochrome C oxidase subunit II (1:100, Abcam) or rabbit anti-glutaminase (1:500,
Thermo Fisher). Lung metastatic tumor burden and the
number of metastases were quantiﬁed in antihuman
cytochrome C oxidase and hematoxylin and eosin stained
lung sections using Aperio ImageScope software; slides
were reviewed by the pathologist (Dr. A. Tuck, London
Health Sciences Center).
Quantitative real-time PCR (qPCR)

Total RNA was extracted from cells using the RNeasy
Mini Kit (Qiagen) and reverse-transcription was carried
out according to manufacturer’s instructions using iScript
RT Supermix (Bio-Rad). Gene expression was determined
using SYBR green real-time qPCR (RT-qPCR) as previously described25. The steady-state mRNA levels of each
gene of interest was determined by ampliﬁcation of cDNA
using speciﬁc primers and the results were normalized to
β-actin. Speciﬁc primers to determine the mRNA levels of
each gene include: GLS (glutaminase) forward primer (F):
AGCTTGTGTGGTCTTCCATGAT and reverse primer
(R): TCATGAAGCTAGGGTGAGAGAGA; GLUL (F): G
GACAATGCCCGACGTCTAA and (R): AGAAGACAC
GTGCGGATGAG; CPSII (F): AGACGCCTATGGCAAC
TGTG and (R): GTCTGCCTCAGGAGCTGATAC. MY
C, SCL1A5 and GLUD primers were purchased from BioRad (validated PCRPrime primers).
Cell growth assays

For glutamine deprivation assay, SKBR3FLAG-KISS1R
cells and controls were seeded in 6 cm dishes (400,000
cells each) in glutamine-free RPMI media with dialyzed
FBS. Cells were treated with 0.02 mM glutamine, 0.2 mM
glutamine, or 2 mM glutamine (Gibco) over 72 h; media
was changed every 24 h and cells trypsinized and counted
using a hemocytometer at 24 h intervals. For BPTES or
CB-839 (Sigma Aldrich) treatment, SKBR3FLAG-KISS1R
cells (400,000 cells) were plated in 6 cm dishes. On the
following day, these cells were treated with different
concentrations of BPTES or CB-839 and cell number
counted at 24 h intervals. To determine the effect of cMyc knockdown on cell growth, SKBR3FLAG-KISS1R
cells expressing c-Myc siRNA were cultured in media
without glutamine. Media was changed daily and each day
cells were counted for each experimental condition.
Scratch assays

These assays were conducted as described25,27.
SKBR3FLAG-KISS1R cells expressing siMYC shRNA or
scrambled controls were plated in duplicate wells, grown
to conﬂuence in a 12-well plate, and scratched with a
sterile pipette tip. Cells in FBS supplemented media were
Ofﬁcial journal of the Cell Death Differentiation Association
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allowed to migrate into the scratch for 18 h, as previously
shown25. Images were taken using a microscope
(EVOSTM FL Imaging System). For each image (per time
point), the width of the scratch (μm) was measured at
sevenpoints along the scratch. The distance migrated was
calculated by subtracting the width of the scratch at each
time point from the width of the scratch at time zero. The
distances migrated into the scratch at each of the sevenpoints/image was averaged to determine the distance
migrated for each well. Cell migration was expressed as
fold over scrambled control. Cells were counted with
trypan blue to determine cell viability.
Metabolomic analysis by liquid chromatography–mass
spectrometry (LC–MS)

Metabolites from serum (10 μL samples) were extracted
using 40 μL of ice-cold methanol, incubated for 20 min at
−20 °C and then centrifuged for 10 min at 16,000 × g and
4 °C. The supernatant was subsequently transferred to
clean tubes; pellets were extracted again with 200 μL of
40:40:20 methanol:acetonitrile:H2O and sat on ice for
10 min prior to centrifugation for 10 min at 16,000 g and
4 °C. Combined supernatants from the ﬁrst and second
extractions (~240 μL total) were further processed with
Phospholipid Removal 1 mL tube (Phenomenex) according to the manufacturer’s instructions. Final extracts were
stored at −80 °C until analysis using LC–MS.
For metabolite extraction from tumors, 25 mg samples
were pulverized using a Cryomill (Retsch) in liquid
nitrogen for 2 min at 25 Hz. Five hundred microliters of
40:40:20 methanol: acetonitrile: H2O with 0.5% formic
acid solution at −20 °C was added to the ground samples
before vortexing and centrifuging for 10 min at 16,000 × g
and 4 °C. Supernatant was subsequently transferred to
clean tubes; the previous step was repeated to extract the
pellets again. Supernatants from the ﬁrst and second
extractions were combined and spun down for 10 min at
16,000 × g at 4 °C to remove protein precipitate from the
supernatant. Five hundred microliters of extract was then
transferred to a clean tube and neutralized with 44 μL of
15% NH4HCO3 solution, resulting in the ﬁnal extract
(stored at −80 °C until analysis using LC–MS).
For metabolite extraction from cultured cells,
SKBR3FLAG-KISS1R and SKBR3pFLAG (control) cells
were plated, left to adhere for 24 h and then serum starved
in RPMI 1640 for 24 h. For experiments with labeled
glutamine, RPMI media without glutamine was used,
containing labeled L-Glutamine [U-13C] or [U-Amide-15N] (Cambridge Isotope Laboratories, Tewksbury,
MA) at a 2 mM concentration. Conditioned media was
collected at 4 and 16 h, spun to remove debris, and frozen
until analysis. Cell metabolites were obtained by lying the
cells in ice-cold lysis buffer consisting of 40:40:20
methanol:acetonitrile:water with 0.5% formic acid. After
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incubation on ice for 5 min, 15% NH4HCO3 was added to
each plate. Lysates were then centrifuged at 15,000 × g for
10 min at 4 °C and the supernatant was transferred to new
tubes and stored at −80 °C. All samples were diluted 50×
in a 40:40:20 methanol:acetonitrile:water with 0.5% formic
acid and loaded in LC–MS for analysis. Each condition
was done in triplicate. Normalization of pool size was
done to pack cell volume, as well as to protein amount
per dish.
LC–MS analysis

LC–MS analysis of cell metabolites was conducted on Q
Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc) alongside hydrophilic
interaction chromatography. The Dionex UltiMate 3000
UHPLC system (Thermo Fisher Scientiﬁc) with XBridge
BEH amide column (Waters, Milford, MA) and XP
VanGuard Cartridge (Waters, Milford, MA) were used for
LC separation. The LC gradient, comprised of solvent A
(95%:5% H2O:acetonitrile with 20 mM ammonium acetate, 20 mM ammonium hydroxide, pH 9.4) and solvent B
(20%:80% H2O:acetonitrile with 20 mM ammonium
acetate, 20 mM ammonium hydroxide, pH 9.4), corresponded with the following solvent B percentages over
time: 0 min, 100%: 3 min, 100%; 3.2 min, 90%; 6.2 min,
90%; 6.5 min, 80%; 10.5 min, 80%; 10.7 min, 70%; 13.5 min,
70%; 13.7 min, 45%; 16 min, 45%; 16.5 min, 100%. Chromatography ﬂow rate was at 300 μL/min and injection
volume 5 μL. Column temperature was maintained at
25 °C. MS scans were set to negative ion mode with a
resolution of 70,000 at m/z 200, in addition to an automatic gain control target of 3 × 106 and scan range of
75–1000. Metabolite data were obtained using the
MAVEN software package as previously described28 with
each labeled isotope (mass accuracy window: 5 ppm).
Labeled isotope natural abundance and impurity were
corrected using the AccuCor package coded in R, as
previously described29.

Results
Plasma kisspeptin levels and glutamine metabolism in
human TNBC

Human TNBC cells secrete KPs25, and KISS1 and
KISS1R mRNA are elevated in human TNBC patient
tumors compared with healthy breast samples25. However,
whether plasma KP levels differ in TNBC patients compared with healthy subjects remains unknown. Thus,
plasma KP levels were measured among the following
patient groups, as previously described30 (see Table 1 for
patient demographics): (1) newly diagnosed, nonmetastatic
TNBC (early disease); (2) metastatic TNBC (advanced
disease), and (3) healthy subjects (no prior history of breast
cancer). The data revealed that plasma KP levels in TNBC
patients were signiﬁcantly higher compared with the levels
Ofﬁcial journal of the Cell Death Differentiation Association
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observed in healthy females (Fig. 1a, nonmetastatic TNBC:
78 ± 5.5 pmol/L (p < 0.0001), metastatic TNBC: 64.9 ± 6.6
pmol/L (p = 0.017), and healthy: 39.1 ± 2.3 pmol/L).
TNBC tumors display dysregulated glutamine metabolism5,31. Similar to previous reports4,32,33, c-Myc and glutaminase (encoded by GLS1) were found to be signiﬁcantly
upregulated in human primary TNBC tumor biopsies
compared with healthy breast tissue (Fig. 1b–f; see Supplementary Fig. 1a for remaining blots); the expression of
both isoforms of GLS1 (KGA, kidney-type glutaminase
and GAC, glutaminase C) was observed in TNBC biopsies
(Fig. 1d, Supplementary Fig. 1a). The presence of epithelial
cells in breast tissue was identiﬁed using cytokeratins,
markers for epithelial cells34–36. Speciﬁcally, mammary
glands in normal breast tissue expressed cytokeratins 8/18
(Fig. 1b, Supplementary Fig. 1b), whereas basal TNBC
tumors robustly expressed cytokeratin 5 (Fig. 1b).
KISS1R expression regulates metastasis in xenograft
models

We have previously shown that KISS1R depletion using
KISS1R shRNA in TNBC cells (MDA-MB-231 and Hs578t)
reduced the expression of mesenchymal markers, cell
migration, invasion, and anchorage-independent growth
without affecting cell viability19, suggesting a role for
KISS1R in malignant transformation. However, whether
human KISS1R regulates metastasis is unknown. Thus,
KISS1R expression was depleted in metastatic MDA-MB231 cells (Fig. 2a, Supplementary Fig. 1c) and tested for its
effect on tumor growth and metastasis in a spontaneous
metastasis xenograft model using NOD/SCID/IL2 receptor
γnull mice27. Stable knockdown of KISS1R reduced primary
tumor volume and the capacity of tumor cells to metastasize and colonize the lungs compared with scrambled
shRNA controls (Fig. 2b–e). Lung metastases were identiﬁed using an antihuman Ki67 (a cell proliferation marker)
and an antihuman cytochrome (cyto) C antibody (Fig. 2c,
middle and right panels).
Since KISS1R knockdown led to reduced primary
tumors (Fig. 2b), which could result in reduced metastasis,
we tested whether KISS1R regulates lung colonization
using an experimental metastasis xenograft model. For
this assay, a gain-of-function approach was employed
using human ERα-negative luminal SKBR3 breast cancer
cells (that express low levels of endogenous KISS1R18,27),
and stably overexpressed FLAG-KISS1R similar to levels
observed in TNBC MDA-MB-231 cells18,25,27. Using this
approach, we previously showed that KISS1R overexpression induced KP secretion and promoted an EMTlike event resulting in an upregulation of mesenchymal
and cell survival markers, and increased cell invasion
in vitro18,25,27. Following tail vein injection, mice injected
with SKBR3FLAG-KISS1R cells had a signiﬁcantly higher
number of lung metastases compared with mice injected

Dragan et al. Cell Death and Disease (2020)11:106

Fig. 1 (See legend on next page.)

Ofﬁcial journal of the Cell Death Differentiation Association

Page 6 of 20

Dragan et al. Cell Death and Disease (2020)11:106

Page 7 of 20

(see ﬁgure on previous page)
Fig. 1 Plasma kisspeptin, c-Myc, and glutaminase are highly expressed in human triple-negative breast cancer (TNBC). a Plasma kisspeptin
(KP) levels (pmol/L; mean ± SEM) measured by radioimmunoassay in blood samples taken from healthy subjects (n = 26), nonmetastatic TNBC
patients (i.e., early disease; n = 25), or metastatic TNBC patients (n = 27). Statistical analysis done using a nonparametric Kruskal–Wallis test. Error bars:
SEM. b Representative images of immunostaining on formalin-ﬁxed and parafﬁn-embedded human breast tissue biopsies showing the lack of
expression of GLS or c-Myc in normal breast tissue, whereas these proteins are enriched in TNBC tumors; staining of epithelial markers cytokeratins 8/
18 (enriched in normal breast tissue mammary glands) and cytokeratin 5 (enriched in basal tumors) shown below. Scale bar, 50 μM; n = 5/cohort.
Representative western blots showing the expression of endogenous c-Myc and glutaminase (GLS1) in breast tissue lysates from (c) six healthy
subjects and (d) 12 TNBC primary tumor biopsies, relative to expression of each protein in MDA-MB-231 cell lysates (positive control); see
Supplementary Fig. 1a for the remaining six TNBC blots. Densitometric analysis of e c-Myc and f GLS1 blots from 12 TNBC biopsies and six normal
breast tissue, conducted by normalizing to GADPH loading controls and protein expression in MDA-MB-231 cell lysates (internal control); Student’s
unpaired t test, *p < 0.05.

with controls (Fig. 2f). Taken together, these results reveal
that human KISS1R induces primary tumor growth and
metastasis.
KISS1R modulates the expression of key regulators of
glutamine metabolism in ERα-negative breast cancer cells

We then sought to determine whether KISS1R regulated the glutamine utilization to thereby support tumor
growth. The major glutamine transporter expressed by
TNBC tumors is the SLC1A5 (also known as ASCT2)32.
Upon entry into the cell, glutamine is converted to glutamate by glutaminase (GLS1). Glutamate can be converted to generate α-ketoglutarate, a TCA cycle
intermediate by glutamate dehydrogenase 1 (encoded by
GLUD1)2. KISS1R overexpression in ERα-negative SKBR3
cells resulted in a signiﬁcant increase in the expression of
c-Myc, GLS1, GLUD1, but decreased expression of glutamine synthetase (encoded by GLUL gene) that converts
glutamate to glutamine (Fig. 3a–e; Supplementary Fig.
1d–j). This suggests that KISS1R overexpressing cells lack
the ability to synthesize glutamine. GLUD1 is essential for
sustaining the TCA cycle in rapidly proliferating cells and
is upregulated in breast cancer37. These data suggest that
KISS1R overexpression may sustain the TCA cycle
required for cell growth and proliferation. Glutamate can
also be converted to a co-factor in the urea cycle, Nacetylglutamate, by N-acetylglutamate synthase (NAGS).
However, NAGS expression was similar between the two
cell lines (Fig. 3e, Supplementary Fig. 1j), indicating that
KISS1R differentially regulates the expression of key glutamine metabolism enzymes. Conversely, KISS1R depletion in TNBC MDA-MB-231 cells revealed a reduction in
the levels of c-Myc, GLS1, and SLC1A5 in KISS1R
knocked-down cells versus controls (Supplementary Fig.
2a–e). Taken together, these data suggest a role for
KISS1R in regulating glutamine metabolism pathway in
ERα-negative breast cancer cells.
KISS1R promotes the dependence on glutamine for
growth

To determine whether KISS1R expressing cells require
glutamine for growth, the effect of glutamine deprivation
Ofﬁcial journal of the Cell Death Differentiation Association

was examined on cell growth. SKBR3FLAG-KISS1R cells
and controls were grown in glutamine-free medium and
treated with increasing concentrations of glutamine daily
over 72 h. Glutamine deprivation (0 and 0.02 mM glutamine) signiﬁcantly inhibited SKBR3FLAG-KISS1R cell
growth compared with cells grown in 0.2 or 2 mM glutamine, the latter being the glutamine concentration in
cell culture media (Fig. 3f). In contrast, no changes were
observed in growth of SKBR3pFLAG controls upon
removal of glutamine (Supplementary Fig. 2h). Then, the
effects of the GLS1 inhibitor BPTES was examined, which
triggers cellular glutamate depletion31,38. Analysis of cell
growth curves revealed that BPTES treatment (≥5 μM)
signiﬁcantly suppressed the growth of SKBR3FLAGKISS1R cells in contrast to controls (Fig. 3g, Supplementary Fig. 2i). Similar observations were made with CB839, another GLS inhibitor that is currently being tested
in Phase I/II clinical trials in various cancers and shown to
attenuate TNBC tumor growth in xenografts39. CB-839
treatment signiﬁcantly inhibited cell growth (Fig. 3h).
This is in agreement with reports that luminal-type cells
(such as the SKBR3 cells) are relatively glutamine independent. In contrast, basal-type SKBR3FLAG-KISS1R
cells exhibit glutamine-dependence for growth.
KISS1R promotes glutamine metabolism in tumors

To investigate whether KISS1R regulates tumor metabolism, the effect of KISS1R overexpression on primary
tumor metabolism was determined using an orthotopic
xenograft model. Primary breast tumor volumes were
signiﬁcantly higher in mice injected with SKBR3FLAGKISS1R cells compared with mice injected with controls
(Fig. 4a, Supplementary Fig. 3a). Human tumor cells were
identiﬁed in primary tumors (Fig. 4b). Immunohistochemical analysis revealed SKBR3FLAG-KISS1R primary
tumors expressed GLS, in contrast to control tumors
(Fig. 4b).
In order to uncover metabolic differences contributing to
the distinct phenotypes observed between SKBR3FLAGKISS1R primary tumors and controls, a global, untargeted
metabolomic analysis of tumors was conducted. KISS1R
overexpression resulted in signiﬁcantly higher glutamate
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Fig. 2 (See legend on next page.)

levels in the primary tumors compared with control tumors
(Fig. 4c), whereas there was no change in glutamine levels
(Fig. 4d). Both serum glutamate and glutamine levels were
signiﬁcantly decreased in SKBR3FLAG-KISS1R xenografts
Ofﬁcial journal of the Cell Death Differentiation Association

compared with controls (Fig. 4e, f). A possible explanation
for this is that the primary tumor utilizes more glutamine
from the serum to promote glutaminolysis, resulting in the
increased glutamate content within the tumor. This might
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Fig. 2 KISS1R expression regulates primary breast tumor growth and metastasis in xenograft models. a–e Depletion of endogenous KISS1R
in human metastatic triple-negative MDA-MB-231 breast cancer cells inhibits primary tumor growth and lung metastases in a spontaneous metastasis
xenograft model. a Representative western blot showing KISS1R expression in lysates from MDA-MB-231 cells stably expressing KISS1R shRNA and
scrambled control used in xenograft experiments; β-actin, loading control. Densitometric analysis of blots shown in Supplementary Fig. 1b. b Primary
orthotopic tumor volumes: mouse mammary fat pad, 106 cells/mouse, n = 5 mice/group. Points represent each mouse mean tumor volume and bars
represent mean volume ± SEM. c Representative images of lung metastasis (outlined in green, left panels) subjected to either hematoxylin and eosin,
antihuman Ki67 (middle panels), or human anti-cytochrome C oxidase. Scale bar, 100 μm. The extent of lung metastasis measured by (d) number of
lung metastases (normalized to 100 mm2) lung and (e) tumor burden in the lung (percentage of lung occupied by tumor); four sections/tissue/
mouse, n = 5 mice per group). Bars represent lung area and number of metastases ± SEM, respectively. One-way ANOVA followed by Dunnett’s
multiple comparison test: *p < 0.05. f KISS1R overexpression promotes lung colonization in a experimental metastasis xenograft model. Lung
metastases (n = 5 mice/group, outlined in green) formed by human ERα-negative SKBR3 breast cancer cells stably expressing FLAG-KISS1R or pFLAG
vector control. Bars represent mean ± SEM. Metastases quantiﬁed blindly in hematoxylin and eosin and human anti-cytochrome C oxidase stained
slides. Student’s unpaired t test: *p < 0.05. Scale bars, 200 μm.

also be due to the elevated levels of glutaminase observed in
SKBR3FLAG-KISS1R tumors (Figs. 3b, e and 4b). Therefore, these data suggest that KISS1R overexpression promotes glutamine metabolism in primary tumors by
upregulating glutaminase expression to thereby promote
tumor growth.
Metabolomic analysis of primary tumors revealed that
several metabolites in the glutamine, nucleotide, and
lipid synthesis pathways and TCA cycle were signiﬁcantly elevated in the SKBR3FLAG-KISS1R tumors
compared with control tumors (Fig. 5a). In addition,
membrane phospholipids such as CDP-choline, phosphocholine, and glycerophosphocholine were signiﬁcantly elevated in SKBR3FLAG-KISS1R primary
tumors (Fig. 5a, Supplementary Fig. 3b). Serum level of
inositol was higher, whereas glycerophosphocholine
level was decreased in SKBR3FLAG-KISS1R xenografts,
compared with controls, likely due to elevated uptake by
tumors (Fig. 5b, c). This suggests an enhanced lipid
synthesis that is characteristic of malignant tumors40,41.
No change in glycolytic metabolites was observed in
SKBR3FLAG-KISS1R tumors versus control tumors
(Supplementary Fig. 3b).
In particular, two metabolites, 2-hydroxyglutarate and
5′-methylthioadenosine were identiﬁed to be signiﬁcantly
increased with KISS1R overexpressing primary tumors
compared with controls (6.1 and 3.9-fold changes,
respectively; Fig. 5a, Supplementary Fig. 3b). The oncometabolite 2-hydroxyglutarate is markedly elevated in
ERα-negative human breast tumors of the basal-like/
mesenchymal subtype and this has been linked to poor
clinical outcome, c-Myc activation, and glutamine
dependence42. The nucleoside 5′-methylthioadenosine
can be used for purine synthesis or enter the methionine
salvage pathway. Methionine is an essential amino acid
required for protein synthesis, methylation of DNA, and
polyamine synthesis43. Methionine can also be converted
to the amino acid cysteine. The levels of cysteine as well as
branched-chain amino acids valine and leucine were elevated in serum from SKBR3FLAG-KISS1R xenografts
Ofﬁcial journal of the Cell Death Differentiation Association

versus controls (Fig. 5d–f). These branched-chain amino
acids can be metabolized to succinyl-CoA or acetyl-CoA
and used in the TCA cycle44. Taken together, these results
highlight KISS1R’s role in metabolic reprograming of
primary tumors in vivo.
KISS1R expression promotes glutaminolysis and TCA cycle
activity in cultured ERα-negative breast cancer cells

Next, metabolic analysis was conducted using cultured
SKBR3FLAG-KISS1R and control cells. In support of
the in vivo data, SKBR3FLAG-KISS1R cells were found
to produce more glutamate, suggesting increased glutamine metabolism (Fig. 6a). Using a 13C5-glutamine
tracer, the utilization of glutamine carbon to form
metabolites was traced (Fig. 6b). Glutamate pool size
(calculated after normalization to the pack cell volume)
was signiﬁcantly larger in the SKBR3FLAG-KISS1R cells
compared with controls (Fig. 6c). Glutamine can be
converted to α-ketoglutarate and thereby provide four
carbons for TCA metabolites. We observed greater
labeling in TCA metabolites (e.g., citrate, aconitate,
fumarate, and malate) in SKBR3FLAG-KISS1R cells,
relative to controls (Fig. 6d–g), suggesting increased
glutamine contribution to TCA cycle intermediates
upon KISS1R expression.
KISS1R expression drives glutamine-dependent nucleotide
synthesis

Glutamine is an important nitrogen source in the
synthesis of pyrimidines (Fig. 6h) and purines (Fig. 7a).
The ﬁrst rate-limiting step in de novo pyrimidine
synthesis requires the enzyme carbamoyl phosphate
synthase II (CPSII) that together with aspartate transcarbamylase and dihydroorotase, forms the trifunctional
CAD enzyme complex. CAD protein (Fig. 6i, Supplementary Fig. 2f) and CPSII mRNA levels (Supplementary
Fig. 2g) were signiﬁcantly upregulated in SKBR3FLAGKISS1R cells relative to controls, indicating that the
pyrimidine synthesis pathway might be altered upon
expression of KISS1R.
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Fig. 3 (See legend on next page.)

Glutamine is converted to glutamate and donates its
amide (γ) nitrogen for nucleotide biosynthesis. Thus, to
examine whether KISS1R regulates pyrimidine synthesis,
Ofﬁcial journal of the Cell Death Differentiation Association

an amide 15N-glutamine tracer was utilized (Fig. 6h).
Results revealed that uridine monophosphate and uracil
have signiﬁcantly increased incorporation of the amide

Dragan et al. Cell Death and Disease (2020)11:106

Page 11 of 20

(see ﬁgure on previous page)
Fig. 3 KISS1R regulates the expression of key proteins involved in glutamine metabolism. Relative mRNA expression of genes regulating
glutamine metabolism by RT-qPCR in SKBR3FLAG-KISS1R breast cancer cells and SKBR3pFLAG vector controls: a c-Myc, b GLS1 (encoding
glutaminase), c GLUL (encoding glutamine synthetase), and d GLUD1 (encoding glutamate dehydrogenase). Columns represent mean relative mRNA
expression, normalized to β-actin ± SEM; Student’s unpaired t test, *p < 0.05. (n = 6). e Representative western blot showing the expression of KISS1R,
KISS1, c-Myc, GLS1, glutamine transporter SLC1A5, and glutamine synthetase in lysates made from SKBR3 cells stably expressing FLAG-KISS1R or
pFLAG vector control. See Supplementary Fig. 1c–j for quantiﬁcation of blots (n = 4). f Effect of glutamine deprivation on SKBR3FLAG-KISS1R cells
growth. Cells (SKBR3FLAG-KISS1R and SKBR3pFLAG controls) were grown in glutamine-free media or treated with different concentrations of
glutamine and counted each day for 3 days to assess cell proliferation. Differences in cell count are expressed as fold change, calculated by dividing
the number of cells from each corresponding day, by that of day 0 (n = 3). See Supplementary Fig. 2h for glutamine deprivation assay on
SKBR3pFLAG controls. *p < 0.05; Two-way ANOVA followed by Bonferroni post hoc test: a glutamine 2 mM vs. 0 mM; b glutamine 2 mM vs. 0.02 mM;
c glutamine 0.2 mM vs. 0 mM; d glutamine 0.2 mM vs. 0.02 mM; e glutamine 2 mM vs. 0.2 mM. Cell proliferation curves of SKBR3FLAG-KISS1R cells
treated daily with glutaminase inhibitors, g BPTES and h CB-839 *p < 0.05; two-way ANOVA with multiple comparisons followed by Bonferroni post
hoc test. Mean and SEM shown; (n = 4); a vehicle vs. 20 μM; b vehicle vs. 10 μM; c vehicle vs. 5 μM. See Supplementary Fig. 2i for BPTES treatment in
SKBR3pFLAG controls. For h: a vehicle vs. 0.5 μM; b vehicle vs. 1 μM.

nitrogen from glutamine in SKBR3FLAG-KISS1R cells
compared with controls (Fig. 6j, k). In line with this data,
SKBR3FLAG-KISS1R primary tumors from xenografts
displayed a signiﬁcant increase in serum levels of the
nucleoside uridine (Fig. 6l). Although we did not observe a
signiﬁcant change in tumor UTP levels, the level of ribose
phosphate, a key intermediate in de novo nucleotide
synthesis was signiﬁcantly elevated in the SKBR3FLAGKISS1R tumors (Fig. 6m, n).
To determine whether KISS1R regulates glutamine
utilization in purine synthesis, an amide 15N-glutamine
tracer was utilized (Fig. 7a). Elevated KISS1R expression
resulted in a signiﬁcant increase in labeled IMP and ATP
after 1 and 4 h compared with controls (Fig. 7b, c). A
signiﬁcant increase in 5′-methylthioadenosine was also
observed in KISS1R overexpressing cells (Fig. 7d), as well
as in primary tumors (Figs. 5a, 7e) compared with their
corresponding controls. 5′-Methylthioadenosine is generated during the biosynthesis of polyamines (Fig. 7a) and
generates purines. Interestingly, deprivation of 5′methylthioadenosine inhibits TNBC metastasis45. Other
metabolites implicated in purine synthesis, such as the
intermediate xanthosine-5′-phosphate (XMP; Fig. 7f) and
the nucleoside guanosine (Fig. 7g) were elevated in
SKBR3FLAG-KISS1R primary tumors and serum levels,
respectively. Taken together, these data suggest that
KISS1R signaling reprograms metabolism in primary
tumors, driving the use of the amide nitrogen from glutamine for nucleotide synthesis.
KISS1R induces c-Myc expression to regulate cell motility
and glutamate production via MAPK

We have previously shown that KISS1R expression in
SKBR3 cells stimulates cell migration and scratch closure
within 24 h, and this is not due to increased cell proliferation25. Since c-Myc can regulate breast tumor
migration46, we determined the effect of c-Myc depletion
in SKBR3FLAG-KISS1R cell migration. Expression of cMyc siRNA (Fig. 8a) demonstrated a modest but
Ofﬁcial journal of the Cell Death Differentiation Association

signiﬁcant decrease in cell migration compared with
scrambled controls in a scratch assay (Fig. 8b). c-Myc has
been shown to promote glutamine addiction in various
cell types47,48. To investigate the role of c-Myc in inducing
glutamine dependency of SKBR3FLAG-KISS1R cells, cells
expressing c-Myc siRNA were grown in glutaminedepleted media. Knockdown of c-Myc signiﬁcantly
increased resistance of SKBR3FLAG-KISS1R to glutamine
starvation compared with controls (Fig. 8c). We also
found that c-Myc depletion in SKBR3FLAG-KISS1R and
MDA-MB-231 cell lines (Fig. 8a, e) signiﬁcantly reduced
the expression of glutamine transporter SLC1A5 (Fig. 8d,
f), although there was no change in GLS expression
(Supplementary Fig. 4a, b). This suggests c-Myc appears
to regulate transcription of genes involved in glutamine
transport, as previously reported48.
It is well known that KISS1R signaling activates
MAPK10,17,25,49 and in TNBC, KISS1R signaling stimulates the phosphorylation of ERK1/2 to promote cell
invasion19,20,27. KISS1R overexpression activates ERK1/2
in SKBR3 cells25 and ERK1/2 activation stabilizes transcription factors such as c-Myc50. Since c-Myc protein
was upregulated in SKBR3FLAG-KISS1R cells (Fig. 3e,
Supplementary Fig. 1f), we determined whether KISS1R
inﬂuenced c-Myc expression post transcriptionally via
ERK1/2. Findings revealed that treating SKBR3FLAGKISS1R cells with an ERK1/2 inhibitor, U0126, resulted in
an inhibition of ERK activity and c-Myc expression and a
concomitant decrease in glutamate production, compared
with cells treated with the inactive analog U0124 or
vehicle controls (Fig. 8g, h). This implies that in addition
to stimulating c-Myc transcription (Fig. 3a), KISS1R
requires MAPK signaling to induce c-Myc protein
expression to thereby maintain the glutaminolytic phenotype, and addiction to glutamine as a bioenergetic
substrate. Taken together, data suggest that KISS1R exerts
its oncogenic functions by inducing c-Myc expression to
thereby enhance glutamine metabolism and facilitate
tumorigenesis (Fig. 8i).
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Fig. 4 KISS1R expression promotes primary breast tumor growth and glutamine metabolism in an orthotopic xenograft model. Six-weekold immunocompromised mice were injected with SKBR3pFLAG controls (2 × 106 cells/mouse) or SKBR3FLAG-KISS1R cells (106 cells/mouse) into the
mammary fat pad. a Primary tumor volume after 6 weeks for animals injected with SKBR3FLAG-KISS1R cells and 8 weeks for animals injected with
SKBR3pFLAG controls. b Representative images of orthotopic primary tumors subjected to hematoxylin and eosin, antihuman cytochrome C oxidase,
or antihuman glutaminase (GLS1); magniﬁed section in white boxed area shown in image below. Metabolites in primary breast tumors (c, d) and
serum (e, f), respectively, from xenografts: c, e glutamate and d, f glutamine levels measured by LC–MS. Student’s unpaired t test, *p < 0.05. (n = 4
mice for SKBR3FLAG-KISS1R xenografts; n = 3 for pFLAG control xenografts).
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Fig. 5 Quantitative analysis of primary tumor and serum metabolites from SKBR3FLAG-KISS1R and SKBR3pFLAG control orthotopic
xenografts. a Volcano plot comparing metabolite levels measured by LC–MS in primary tumors of SKBR3FLAG-KISS1R xenografts versus those of
SKBR3pFLAG controls. The fold change between the two groups and p values for each metabolite are plotted and represented in a bar graph
(Supplementary Fig. 3b). Fold changes >1 and <1 indicate increases and decreases, respectively, in metabolite levels in SKBR3FLAG-KISS1R and
control tumor groups. Student’s two-tailed t test, *p < 0.05. Metabolites in serum: b inositol, c glycerophosphocholine, d cysteine, e valine, and f
leucine.
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Fig. 6 KISS1R expression promotes glutaminolysis, increases glutamine ﬂux to tricarboxylic acid (TCA) cycle metabolites, and stimulates
glutamine-dependent nucleotide synthesis. a Production rate of glutamate measured in the conditioned media after 4 or 16 h of culturing
SKBR3pFLAG controls or SKBR3FLAG-KISS1R cells grown in serum-free media (unlabeled). b Schematic showing the transfer of carbon atoms of the
13
C5-labeled glutamine tracer used to detect glutamine ﬂux into TCA cycle intermediates; labeled carbon atoms (red) and unlabeled carbon atoms
(white). c Glutamate pool size from 13C5 glutamine tracer in cells. d–h Relative fractions of 13C5 glutamine tracer in TCA cycle metabolites d citrate,
e aconitate, f fumarate, and g malate. Normalization of pool size was done to pack cell volume per dish. Mean ± SEM shown (n = 3). *p < 0.05,
Student’s unpaired t test. h Schematic of the pyrimidine synthesis pathway showing the contribution of the amide nitrogen using a 15N-glutamine
tracer. Diamonds indicate nitrogen, labeled for amide (red) and unlabeled (white). Diamond with subscript α denotes the alpha nitrogen of
glutamine. i Representative western blot of the CAD enzyme complex in lysates from SKBR3FLAG-KISS1R and SKBR3pFLAG vector control cells. See
Supplementary Fig. 2f for quantiﬁcation of blots. Fraction of glutamine’s amide nitrogen contributing to pyrimidine synthesis metabolites: j UMP and
k uracil in cultured SKBR3FLAG-KISS1R and SKBR3pFLAG control cells (n = 3). Levels of pyrimidine synthesis metabolites measured by LC–MS in
orthotopic breast tumors and serum from xenografts: l serum uridine; primary tumor (m), UTP (n) ribose phosphate. Student’s unpaired t test, *p <
0.05. (n = 4 mice for SKBR3FLAG-KISS1R xenografts; n = 3 for SKBR3pFLAG control xenografts).

Discussion

The ﬁndings reported here demonstrate for the ﬁrst
time that human KISS1R promotes TNBC tumor
growth and metastasis using preclinical xenograft
models. In support of our ﬁndings, murine Kiss1r
promotes metastasis in a mouse mammary tumor virus
model51. KISS1R is a strong candidate for targeted
therapy since it is highly expressed in patient TNBC
tumors, in contrast to normal breast25. Importantly
although infertile, mice lacking KISS1R exhibit no
other overt developmental defects10. KISS1R is a key
regulator of pubertal onset and fertility9 and plasma
KPs in humans increase dramatically in puberty
(~50–60pmol/L) and during pregnancy (~11,000 fmol/
mL in the third trimester)9,10, where the placenta is
suggested to be a major source of the circulating KPs
(reviewed10). Despite the small cohort size, we found
that plasma KP levels were elevated in TNBC. Thus, a
rise in plasma KPs may inﬂuence metabolic reprogramming during oncogenic transformation, although
this is yet to be tested. This suggests that KISS1R could
potentially serve not only as an adjunct therapeutic
target but also as a marker for surveillance of disease
recurrence or metastasis, which requires further
investigation. KISS1/KISS1R expression are upregulated in TNBC patient tumor biopsies and high KISS1
expression has been shown to correlate with increase in
lymph node metastasis52. Our future studies will
examine the clinical relevance of KP/KISS1R signaling
in other breast cancer subtypes, which have a distinct
molecular characteristics and clinical regiments, compared with TNBC1,53.
Previous work has shown that KISS1 and KISS1R levels
are upregulated in invasive ERα-negative breast cancer
cells (e.g., MDA-MB-231, Hs578T, SKBR3FLAG-KISS1R)
in contrast to weakly invasive, ERα-positive luminal breast
cancer cells (T47D, MCF7) or ERα-negative luminal
SKBR3 cells25. KP failed to stimulate invasiveness of T47D
or MCF7 cells, or upon reexpression of ERα in TNBC
MDA-MB-231 cells18; in the latter, estradiol resulted in a
Ofﬁcial journal of the Cell Death Differentiation Association

downregulation of KISS1/KISS1R levels18,21. This negative
regulation by estradiol signaling also occurs in the brain54.
In line with these observations, placental KPs induce ERαnegative breast cancer cell invasion, whereas cell invasion
of ERα-positive breast cancer cells was inhibited55.
Interestingly, a recent study showed that TGFβ promotes
TNBC cell invasion by inducing KISS1 expression, by
regulating MMP-9 levels52.
Another new ﬁnding is that in addition to regulating
tumor growth and metastasis in vivo, KISS1R regulates
metabolic changes in tumors. Compared with luminal
cells e.g., ERα-negative SKBR3, basal-like TNBC cells
such as MDA-MB-231 have been shown to preferentially consume more glutamine than glucose, display deregulated glutaminolysis, and require GLS for
growth and survival31,56. GLS1 knockdown in MDAMB-231 cells inhibits tumor growth in xenografts31. Our
data suggest that KISS1R overexpression changes the
metabolic proﬁle of the SKBR3 cells appearing to make
them more basal like and dependent on glutamine for
survival. Metabolomic analyses of human primary
tumor biopsies revealed elevated levels of glutamate in
TNBC tumors versus ERα-positive tumors5–7.
The MYC oncogene is overexpressed in TNBC compared with other breast cancer subtypes57,58 where it
promotes EMT and metastasis46. c-Myc is a master regulator of metabolic pathways and stimulates glutaminolysis, leading to glutamine addiction59 by regulating the
expression of GLS3 and SLC1A532,60. SLC1A5 is highly
expressed in TNBC patients32 and SLC1A5 activity is
critical for TNBC cell growth but not for the growth of
luminal breast cancer32. We found that KISS1R induced
the expression of c-Myc to thereby promote the
glutamine-dependency phenotype. Furthermore, KISS1R
appears to promote glutamine uptake by the tumors by
inducing SLC1A5 transcript levels in a c-Myc-dependent
manner. Glutamine is converted to glutamate by GLS1
and is used to support crucial pathways including
nucleotide biosynthesis, TCA cycle, and amino acid
synthesis in proliferative ERα-negative tumors (Fig. 8i).
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Fig. 7 KISS1R expression promotes purine synthesis. a Diagram of the purine synthesis pathway, including the amide nitrogen glutamine tracer.
Diamonds indicate nitrogen, labeled for amide (red) and unlabeled (white). Diamond with subscript α denotes the alpha nitrogen of glutamine.
Fractional enrichment of glutamine’s amide nitrogen contributing to metabolites in purine synthesis in SKBR3FLAG-KISS1R and pFLAG control cells
(n = 3): b IMP, c ATP, and d 5-methylthioadenosine. Metabolite levels in orthotopic primary tumors of e 5-methylthioadenosine and f xanthosine-5′phosphate and g serum guanosine levels in SKBR3FLAG-KISS1R and SKBR3pFLAG control xenografts (n = 4 mice for FLAG-KISS1R xenografts; n = 3
for pFLAG controls). Mean ± SEM shown. *p < 0.05, Student’s unpaired t test.

Although KISS1R-induced GLS transcription, this
appears to occur in a c-Myc-independent manner. Several
other studies have shown that altering c-Myc levels has no
effect on GLS1 expression, similar to our ﬁndings3,61–63
suggesting that GLS may be regulated by KISS1R via
Ofﬁcial journal of the Cell Death Differentiation Association

alternate mechanisms. Our future work will evaluate the
role of c-Myc in stimulating KISS1R-induced tumor
growth and metastasis in vivo.
Increased KISS1R expression in primary tumor xenografts resulted in elevated levels of the oncometabolite 2-
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Fig. 8 KISS1R induces c-Myc expression to regulate glutamate production via MAPK. a c-MYC mRNA and protein expression in SKBR3FLAGKISS1R cells expressing c-MYC siRNA or control siRNA (Con) constructs, 72 h after transfection. (n = 5). b Representative images of the scratch assay to
assess cell motility of SKBR3FLAG-KISS1R cells transfected with c-MYC siRNA or control siRNA at 0 and 18 h (n = 3). Scale bars, 300 μm. Scrambled cells
migrated 548.2 ± 14.72 μM. Bars show mean ± SEM. Student’s unpaired t test, *p < 0.05. c-Myc-suppressed SKBR3FLAG-KISS1R cells are resistant to
glutamine starvation. Cells expressing c-MYC siRNA were plated in the presence of glutamine and then cultured in the absence of glutamine and
counted each day to assess cell proliferation. Differences in cell count are expressed as fold change, calculated by dividing the number of cells from
each corresponding day, by that of day 0 *p < 0.05; two-way ANOVA with multiple comparisons followed by Bonferroni post hoc test. Mean and SEM
shown (n = 3). a, c control vs. siMYC1; b, d control vs. siMYC2. d SLC1A5 mRNA expression in SKBR3FLAG-KISS1R cells expressing c-MYC siRNA or
control siRNA. (n = 5), e c-MYC mRNA and protein expression, and f SLC1A5 mRNA in MDA-MB-231 cells expressing c-MYC siRNA or control siRNA
constructs, 72 h after transfection. (n = 5). g Representative western blots showing endogenous c-Myc expression in SKBR3FLAG-KISS1R cells treated
with vehicle, 10 µM U0126 (ERK1 and ERK2 inhibitor), and 10 µM U0124 (inactive U0126 analog). Densitometric analysis of blots shown for c-Myc
normalized to housekeeping (GAPDH) and p-ERK normalized to total ERK expression (n = 3). h Glutamate production rate measured in the unlabeled
conditioned media of SKBR3FLAG-KISS1R cells grown in the presence of U0126, U0124 or vehicle (n = 3). i Schematic of the KISS1R signaling pathway
in cancer metabolism. Pathway shown in red is a potential mechanism by which KISS1R promotes glutamine uptake by the tumors to thereby
regulate tumorigenesis.

hydroxyglutarate that accumulates at higher levels in basallike TNBC tumors versus ERα-positive tumors, is associates
with poor patient prognosis5,42 and triggers cell transformation and epigenetic reprogramming. 2-Hydroxyglutarate
accumulation induces c-Myc activation and higher glutamine utilization via GLS160. 2-Hydroxyglutarate can also
activate mammalian target of rapamycin complex 1
(mTORC1)64. In doing so, mTORC1 promotes glutamine
anaplerosis, replenishing the TCA cycle metabolites by
activating GLUD for the production of α-ketoglutarate from
glutamate65. In addition, 2-hydroxyglutarate can increase
reductive carboxylation to generate citrate and supports the
synthesis of acetyl-CoA and lipids2. This might be a possible
explanation for the increased membrane lipids observed in
primary SKBR3FLAG-KISS1R tumor xenografts. Although
KISS1R expression modulates GLUD transcript levels, it
remains to be investigated whether KISS1R regulates
mTORC1.
In summary, this study highlights the role of KISS1R as a
driving force in TNBC metastasis, promoting the glutamine
dependence of tumors to support their growth. Compared
with other breast cancer subtypes, TNBC patients have the
worst prognosis with no approved targeted therapies1.
Inhibitors for GLS as well as for the glutamine transporter
SCL1A5 are currently in clinical trials for the treatment of
TNBC patients66–68. Thus, a combined strategy that targets
KISS1R signaling coupled to the use of inhibitors of glutamine metabolism are vital to minimize toxicity and may
hold great therapeutic promise to improve the clinical
management of TNBC patients.
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